TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01513590

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin degludec/insulin aspart
Description: Administered s.c. (under the skin) twice daily. Dose individually adjusted. Pre-trial metformin treatment to be continued.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart
Description: Administered s.c. (under the skin) twice daily. Dose individually adjusted. Pre-trial metformin treatment to be continued.
Study: NCT01658839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost ophthalmic solution, 0.004% (new formulation)
Description: Travoprost ophthalmic solution, 0.004%, new formulation
Study: NCT03421587

Intervention type: BEHAVIORAL
Intervention: Processing of social olfactory and tactile stimuli
Description: Processing of social olfactory and tactile stimuli in trauma-exposed individuals and controls is examined using functional magnetic resonance imaging.

Intervention type: BEHAVIORAL
Intervention: Processing of social olfactory and tactile stimuli
Description: Processing of social olfactory and tactile stimuli in trauma-exposed individuals and controls is examined using functional magnetic resonance imaging.
Study: NCT03704077

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Relatlimab + Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Relatlimab + Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Relatlimab + Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Specified dose on specified days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramucirumab
Description: Specified dose on specified days
Study: NCT01167244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-690514
Description: Tablets, Oral, 200 mg, once daily, until disease progression or toxicity
Study: NCT00977119

Intervention type: OTHER
Intervention: Side-effect questionnaires
Description: Paper or telephone questionnaire to report specific side-effects associated with their breast cancer treatment weekly

Intervention type: OTHER
Intervention: research blood samples
Description: Blood samples for research on DNA before starting treatment and after 4 cycles of treatment
Study: NCT03144232

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active rTMS
Description: rTMS will be delivered via a MagPro double blinded rTMS Research System (MagVenture, Denmark) with a Cool-B65 Butterfly Coil (a combined active and sham coil). We will use a standard resting motor threshold (rMT) determination to determine the TMS dose. Study-treatment will be delivered at 120% rMT. Each active rTMS study-treatment will consist of a total of 4000 pulses of 10Hz stimulation (5s-on,10s-off). Study-treatments will be delivered at the EEG coordinate for F3 (which approximates the left DLPFC), and will be found using the Beam-F3 method.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: Sham sessions will be delivered using an electronic sham system consisting of a coil that mimics the appearance and sound of rTMS, combined with a TENS device which produces a small electric shock mimicking the feeling of active rTMS. This type of sham has been demonstrated to be indistinguishable from active rTMS.
Study: NCT01404481

Intervention type: DEVICE
Intervention: clean intermittent self catheterisation single use vs re use
Description: Over the 16 week period all patient will participate in 8 weeks of single use cathetersation and 8 weeks of re use catheterisation. The study is a randomised control crossover trial

Intervention type: DEVICE
Intervention: clean intermittent self catheterisation single use vs re use
Description: Over the 16 week period all patient will participate in 8 weeks of single use cathetersation and 8 weeks of re use catheterisation. The study is a randomised control crossover trial
Study: NCT04239378

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: socket preservation
Description: Autogenous dentin matrix and collagen membrane(test group) Bovine derived xenograft and collagen membrane (control group)
Study: NCT02833909

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: surgery
Study: NCT04239378

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: socket preservation
Description: Autogenous dentin matrix and collagen membrane(test group) Bovine derived xenograft and collagen membrane (control group)
Study: NCT02969655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daprodustat small
Description: Available as 7.0 millimeter (mm) round, standard biconvex, white film coated tablets containing 1 mg, 2 mg, or 4 mg of daprodustat as active ingredient

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daprodustat small placebo
Description: Available as 7.0 mm round, standard biconvex, white film coated tablets containing no daprodustat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daprodustat large
Description: Available as 9.0 mm round, standard biconvex, white film coated tablets containing 6 mg of daprodustat as active ingredient

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daprodustat large placebo
Description: Available as 9.0 mm round, standard biconvex, white film coated tablets containing no daprodustat
Study: NCT02969655

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin alfa
Description: Available as 0.5 mL plastic prefilled syringes (PFS) for IV injection each containing 10, 15, 20, 30, 40 or 60 mcg of darbepoetin alfa in a clear and colorless solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa placebo
Description: Available as 0.5 mL plastic PFS for IV injection containing no darbepoetin alfa in a clear and colorless solution.
Study: NCT04226157

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home Blood Pressure Monitoring Device (Qardio Arm)
Description: The Home Blood Pressure Device with telemonitoring capability will allow the participants and physician to monitor blood pressure over time and titrate blood pressure medications as needed for persistently elevated blood pressure.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Primary Care Provider Blood Pressure Management
Description: Participant will follow up as would normally do with primary care provider for blood pressure management.
Study: NCT04547699

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: A single step culture medium
Description: A single step culture medium (SSCM; Global, Life Global)+5mg/ml life global protein, without supplementation of CYK

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: A single step culture medium
Description: A single step culture medium (SSCM; Global, Life Global)+5mg/ml life global protein, without supplementation of CYK

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: A single step culture medium
Description: A single step culture medium (SSCM; Global, Life Global)+5mg/ml life global protein, without supplementation of CYK
Study: NCT03479554

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early antihypertensive treatment
Description: The CATIS 2 trial is designed to test BP reduction strategies-early antihypertensive treatment vs. delayed antihypertensive treatment-rather than test the efficacy of individual antihypertensive drugs. Several antihypertensive agents, including angiotensin-converting enzyme inhibitors, calcium channel blockers, and diuretics will be used in the trial.~BP-lowering treatment will start immediately after randomization in the early antihypertensive treatment group. The target treatment goals are:~* Step 1 (within 24 hours after randomization): To lower systolic BP by 10-20% with an average of 15% (but systolic BP not lower than 130 mmHg and diastolic BP not lower than 80 mmHg) within the first 24 hours after randomization based on the participant's admission BP levels.~* Step 2 (within 7 days after randomization): To achieve systolic BP below 140 mmHg (but not lower than 120 mmHg) and diastolic BP below 90 mmHg (but not lower than 70 mmHg) and maintain this BP level afterward.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Delayed antihypertensive treatment
Description: All home antihypertensive medications will be discontinued in the first seven days after randomization. Study participants will receive antihypertensive treatment on day eight after randomization and will target systolic BP \<140 mmHg (but not lower than 120 mmHg) and diastolic BP \<90 mmHg (but not lower than 70 mmHg) in two weeks. A BP check-up visit will be conducted in two weeks. If BP treatment goal is not achieved, antihypertensive medication will be titrated or a new medication will be added.
Study: NCT04497623

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Invasive mechanical ventilation using the Unisabana-Herons Ventilator during 24 hours
Description: Recruited patients will receive volume-controlled mechanical ventilation (assist-control mode) using the Unisabana-Herons ventilator for 24 hours. Information on clinical, hemodynamic, and respiratory variables will be recorded from 30 minutes before the start of mechanical ventilation with the Unisabana-Herons ventilator. Recordings will be made in the first 4 hours every 15 minutes in the CFR, except for arterial blood gases which will be taken every 30 minutes. In the following 20 hours, arterial blood gas controls will be taken at hour 12 from the start of the ventilator and at hour 24. Other hemodynamic and respiratory variables will be recorded every hour from hour 4 of ventilator start until hour 24.
Study: NCT01383148

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TG4010
Description: TG4010 • TG4010 will be administered starting on Day 1 (D1) of Cycle 1 of chemotherapy and will be administered weekly for 6 weeks by subcutaneous (SC) injections and then once every 3 weeks until progression or discontinuation due to any reason.~Chemotherapy (and bevacizumab if prescribed), will be given as 21-day cycles for a minimum of 4 cycles and up to 6 cycles.~First line therapy:~* Non-squamous carcinoma: pemetrexed + cisplatin or paclitaxel + carboplatin +/- bevacizumab~* Squamous carcinoma: gemcitabine + cisplatin or paclitaxel + carboplatin~Maintenance therapy:~• Pemetrexed or erlotinib for eligible patients and according to labeling.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Placebo will be administered starting on D1 of Cycle 1 of chemotherapy and will be administered weekly for 6 weeks by SC injections and then once every 3 weeks until progression or discontinuation due to any reason.~* First line therapy: as in Arm 1~* Maintenance therapy: as in Arm 1
Study: NCT04130269

Intervention type: OTHER
Intervention: No intervention
Description: Questionnaires, lab-run
Study: NCT00850577

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Solution, IV, 200 mg/m2, Q21days, 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Solution, IV, 200 mg/m2, Q21days, 6 cycles
Study: NCT02212184

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Diaphragm Release Technique
Description: The therapist performs manual contact (pisiform, ulnar edge and the last three fingers) with the underside of the costal cartilage of the 7th, 8th, 9th and 10th rib, and guiding forearms toward the shoulders of the corresponding side. During inspiration, pulls the points of contact with both hands, in the direction of the head, accompanying the elevation movement of the ribs. During exhalation, deepens contact toward the inner costal, maintaining resistance. 2 sets x 10 breaths (1 min interval). Treatment will last two weeks (6 sessions) All patients will undertake four evaluations throughout treatment: Baseline Day 1 and post Day 1; Baseline Day 6 and post Day 6.
Study: NCT00850577

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Solution, IV, AUC=6, Q21days, 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Solution, IV, AUC=6, Q21days, 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CT-322
Description: Solution, IV, 2 mg/kg, Q7days, Until PD
Study: NCT02212184

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Manual Diaphragm release technique (sham)
Description: Manual Diaphragm release technique (sham) In attempt to execute the sham protocol the therapist performs manual contact (pisiform, ulnar edge and the last three fingers) with the underside of the costal cartilage of the 7th, 8th, 9th and 10th rib. The therapist will hold only light touch in the landmarks, without exerting pressure or traction. The maneuver will be performed in two sets of ten deep breaths, with an one minute interval between them.
Study: NCT00850577

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Solution, IV, 15 mg/kg, Q21days, Until PD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab placebo (ie saline solution)
Description: Solution, IV, 0 mg/kg, On days 8 and 15 of a 3-weekly cycle, Until PD
Study: NCT00452569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Oral thalidomide (100mg or 200mg or 400 mg/day) administered to the patient once daily until progression of the disease and for a maximum of 336 + 36 days (12 cycles of 28 +/- 3 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Oral thalidomide (100mg or 200mg or 400 mg/day) administered to the patient once daily until progression of the disease and for a maximum of 336 + 36 days (12 cycles of 28 +/- 3 days).
Study: NCT00929643

Intervention type: OTHER
Intervention: no intervention
Description: success of the initial empiric treatment
Study: NCT00740857

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2 placebo gels capsules delivered as a single dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ibuprofen Formulation 1
Description: 2 marketed ibuprofen gels

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ibuprofen Formulation 2
Description: 2 marketed ibuprofen gels
Study: NCT04039009

Intervention type: DIAGNOSTIC_TEST
Intervention: Pelvic Organ Prolapse Quantification system
Description: The Pelvic Organ Prolapse Quantification system assessment tool measures nine anatomical points and distances in the vagina. The hymen is the reference point to which the other points are compared. The prolapsed organs are measured in centimeters to the hymen with an examination ruler.
Study: NCT00452569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Oral thalidomide (100mg or 200mg or 400 mg/day) administered to the patient once daily until progression of the disease and for a maximum of 336 + 36 days (12 cycles of 28 +/- 3 days).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: High dose oral dexamethasone will be administered at a dose of 40mg/day on days 1-4, 9-12 and 17-20 of each 28-day cycle for cycles 1-4. Beginning with cycle 5, the oral dexamethasone dosing schedule will be reduced to 40mg/day on days 1-4 of each 28-day cycle. Dexamethasone will be administered until progression of the disease and for a maximum of 336 +/- 36 days (12 cycles of 28 +/- 3 days).
Study: NCT04121143

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: IL-17A Antagonist
Description: SHR-1314 subcutaneous injection
Study: NCT03227419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab Prefilled Syringe
Description: Treatment arm: tocilizumab (RoActemra®):~162 mg weekly a schema for therapeutic adaptation with injection intervals determined according to transaminase levels or blood cell counts (neutropenia, thrombopenia) as recommended by Roche-Chugaï (see table below).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept Prefilled Syringe
Description: Treatment arm: abatacept (Orencia®)~125 mg weekly after an initial dose of 500 mg (body weight \<60kg), 750 mg (body weight between 60 and 100 kg), or 1000 mg (body weight \>100 mg) 24 hours before the first subcutaneous injection.
Study: NCT03791944

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3DV+TPS/VARIAN
Description: Use imported 3DV+TPS to map targets and develop treatment plans

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TPS / VARIAN
Description: Use imported TPS to map targets and develop treatment plans

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3DV + TPS / Domestic Accelerator
Description: Use domestic 3DV+TPS to delineate target areas and develop treatment plans

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TPS / Domestic Accelerator
Description: Use domestic TPS to map targets and develop treatment plans
Study: NCT04121143

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IL-17A Antagonist
Description: SHR-1314 subcutaneous injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IL-17A Antagonist
Description: SHR-1314 subcutaneous injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IL-17A Antagonist
Description: SHR-1314 subcutaneous injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: placebo subcutaneous injection to maintain consistency and to prevent blindness

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebos
Description: placebo subcutaneous injection to maintain consistency and to prevent blindness

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebos
Description: placebo subcutaneous injection to maintain consistency and to prevent blindness
Study: NCT02701634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ENTO
Description: Tablets administered orally
Study: NCT04662515

Intervention type: PROCEDURE
Intervention: Type of surgery
Description: surgical or non-surgical extraction one or more teeth

Intervention type: PROCEDURE
Intervention: Type of surgery
Description: surgical or non-surgical extraction one or more teeth
Study: NCT02701634

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets administered orally
Study: NCT04662515

Intervention type: DRUG
Intervention: Dabigatran
Study: NCT02765165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: USL311
Description: Administered once weekly in a 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: USL311
Description: Administered once daily in a 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: USL311
Description: Administered once daily in a 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: USL311
Description: Administered once daily in a 42-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: USL311
Description: Administered once daily in a 42-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lomustine
Description: Administered once every 6 weeks in a 42-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lomustine
Description: Administered once every 6 weeks in a 42-day cycle
Study: NCT02511717

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous tibial nerve stimulation
Description: Patch electrodes applied posterior to the medial malleolus, and 5-10 cm above the medial malleolus of the same leg, just behind the medial tibial edge. Bipolar stimulation setting will be used, with a frequency of 10 Hz, 200ms pulse, and the amplitude will be titrated up to patient's maximum nonpainful tolerance (between 0.5-10mA). This will be done by the patients at home 3x/week for 30 minutes, over 12 weeks.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham transcutaneous tibial nerve stimulation
Description: Patch electrodes applied posterior to the lateral malleolus, and 5-10 cm above the lateral malleolus of the same leg. Bipolar stimulation setting will be used, with a frequency of 10 Hz, 200ms pulse, and the amplitude will be set a 1mA. This will be done by the patients at home 3x/week for 30 minutes, over 12 weeks.
Study: NCT04059952

Intervention type: DEVICE
Intervention: Electroconvulsive Therapy
Description: Electrical currents are passed through the brain to intentionally trigger a controlled seizure in order to produce a therapeutic change in neuro-chemistry and circuitry.

Intervention type: DEVICE
Intervention: Electroconvulsive Therapy
Description: Electrical currents are passed through the brain to intentionally trigger a controlled seizure in order to produce a therapeutic change in neuro-chemistry and circuitry.
Study: NCT04662515

Intervention type: DRUG
Intervention: Rivaroxaban
Study: NCT06033469

Intervention type: DRUG
Intervention: Infliximab
Description: Pediatric patients with IBD suitable for treatment with infliximab

Intervention type: DRUG
Intervention: Adalimumab
Description: Pediatric patients with IBD suitable for treatment with adalimumab
Study: NCT02438579

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nasal Irrigation & Gargling
Description: Participants are advised to perform the intervention as frequently as required (expected frequency around 6 times a day for the first two days, reducing in frequency from day 3 as symptoms improve).
Study: NCT04096131

Intervention type: PROCEDURE
Intervention: cataract surgery
Description: phacoemulsification
Study: NCT02026297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: 1 gram IV over 10 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo; Normal Saline
Description: 0.9% Normal Saline
Study: NCT00300599

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Positive Airway pressure
Description: Continuous positive pressure device with a time clock

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03658525

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MR LINAC
Description: MR GUIDED PROSATE RADIOTHERAPY
Study: NCT00481039

Intervention type: PROCEDURE
Intervention: Medical history and basic laboratory analysis
Description: Medical history and basic laboratory analysis